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Available online 7 February 2016Objective: Cognitive deﬁcits are common in epilepsy, though the impact of epilepsy on cognition in older adults is
understudied. This study aimed to characterize cognition in older adults with epilepsy compared with healthy
older adults and identify potential risk factors for impairment.
Methods: Thirty-eight older adults with epilepsy and 29 healthy controls completed a comprehensive neuropsy-
chological battery, as well as measures of depression and anxiety. Chart review for current medications, seizure
history, and neuroimagingwas also completed. To compare cognitive performance between groups, ANOVAwas
used, and linear regression identiﬁed predictors of impairment among the group with epilepsy.
Results: Patients with epilepsy performed worse across nearly all cognitive domains, and were clinically impaired
(i.e., ≥1.5 SD below mean) on more individual tests when compared with controls, including a subset of patients
with epilepsy with normal MRIs. For all patients with epilepsy, taking a greater number of antiepileptic drugs was
associated with poorer language and visuospatial abilities, and higher anxiety was associated with poorer visual
memory.
Conclusions:Older adults with epilepsy demonstrated greater cognitive deﬁcits thanmatched controls. Polytherapy
and anxiety heightened the risk for cognitive impairment in some cognitive domains, but not in others. Understand-
ing the nature of cognitive decline in this population, as well as associated risk factors, may assist in the differential
diagnosis of cognitive complaints and improve the design of treatment studies for older patientswith epilepsy. Rep-
lication in larger, longitudinal studies is warranted to generalize these ﬁndings.
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The incidence of epilepsy in adults increases signiﬁcantly with
advancing age, particularly in those over the age of 60 years [1]. Com-
pared with healthy controls, older adults with epilepsy demonstrate
deﬁcits across numerous cognitive domains [2–4]. Older adults with ep-
ilepsy also demonstrate deﬁcits when compared with individuals with
known cognitive impairment. For example, Grifﬁth et al. [4] found
that older adults with epilepsy demonstratedworse performance on as-
pects of the Dementia Rating Scale (DRS), a measure of global cognitive
functioning, and letter ﬂuency when compared with individuals withd cognitive impairment; AEDs,
I; BAI, Beck Anxiety Inventory;
hode Island Hospital, 593 Eddy
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).amnestic mild cognitive impairment (MCI). Moreover, they performed
similarly to those with amnestic MCI on all other measures [4].
The relationship between cognitive decline and epilepsy characteris-
tics is complex and still incompletely understood. The available literature
has demonstrated that the duration of seizure disorder and age of onset
correlatedwithmemory performance, with longer seizure duration asso-
ciated with worse performance, and a later age of onset associated with
better performance [2]. Individualswith refractory temporal lobe epilepsy
for more than 30 years also demonstrated lower full scale IQ scores com-
paredwith those with shorter duration of illness [5]. The negative impact
of antiepileptic drugs (AEDs), particularly AED polytherapy, on cognition
has been cited consistently. Individuals on AED monotherapy have per-
formedworse than controls onmeasures of conceptualization and verbal
learning. Moreover, when comparedwith AEDmonotherapy and healthy
controls, polytherapy was associated with worse overall performance on
the DRS as well as poorer performance on the DRS subtests of attention,
initiation/perseveration, andmemory, and delayed recall on a storymem-
ory task [2]. Antiepileptic drug polytherapy has also surfaced as a signiﬁ-
cant predictor of poorer performance on additional tasks of attention,
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polytherapy had worse cognitive performance compared with those
with MCI taking a cholinesterase inhibitor [4].
Previous work has also found that older adults with epilepsy en-
dorsed higher levels of depression than controls, and that depression
was negatively correlated with performance on tasks of memory, ﬂuen-
cy, and global cognition [2]. To our knowledge, the relationship between
anxiety and cognitive function has not been systematically examined in
the older adult population with epilepsy.
Through a comprehensive neuropsychological battery, the current
study aimed to expand on previous work by more precisely characteriz-
ing the nature and prevalence of cognitive deﬁcits in older adults
with epilepsy.We also sought to identify speciﬁc risk factors for cognitive
impairment within this population by examining the impact of epilepsy-
related factors (i.e., age of onset, seizure frequency in past month, total
AEDs, AEDs with well-established cognitive side effects), as well as psy-
chiatric factors (i.e., depression and anxiety) on cognitive performance.
Our study extends previouswork through the inclusionof anxiety as a po-
tential risk factor for cognitive impairment and by examination of the im-
pact of speciﬁc AEDs on cognition, particularly those with known
cognitive side effects. A greater understanding of the nature of cognitive
deﬁcits among older adults with epilepsy, as well as the associated risk
factors, would help guide treatment selection in this population.
2. Methods
2.1. Participants
This researchwas approved by theRhode IslandHospital Institution-
al Review Board, and all study participants provided written informed
consent prior to initiating study procedures. Thirty-eight adults with
epilepsy and twenty-nine cognitively intact adults, 55 years of age or
older, participated in the current study. Patients with epilepsy were re-
cruited through a hospital-based neurology practice, and controls were
recruited through community advertising. Individuals in the groupwith
epilepsy had documented epilepsy as diagnosed by a neurologist.
Healthy controls had no history of seizures or epilepsy and no current
cognitive complaints. Exclusion criteria for both groups included a his-
tory of intellectual disability or other serious developmental disorder;
progressive CNS disorders (e.g., dementia, demyelinating conditions,
Parkinson's disease); signiﬁcant hepatic, renal, or cardiopulmonary con-
dition; brain injury beyond concussion; severe psychiatric conditions
(e.g., schizophrenia, bipolar disorder); and substance abuse disorders
within the past 6 months.
2.2. Measures
2.2.1. Emotional functioning
All participants completed the Beck Depression Inventory—II (BDI-II)
[6] and the State-Trait Anxiety Inventory (STAI) [7]. A higher score on the
BDI-II is indicative of greater levels of depressive symptomatology. Total
score on the trait component of the STAI was computed to determine
levels of chronic anxiety, with higher scores reﬂective of greater levels
of anxiety.
2.2.2. Epilepsy characteristics
A comprehensive history was taken for each older adult with epi-
lepsy. Speciﬁc characteristics examined in the current study included:
age of ﬁrst seizure, patient's reported seizure frequency over the past
month, and total number of currently prescribed AEDs. Antiepileptic
drugs were further categorized based on the presence/absence of
known cognitive side effects.Medicationswith themost clinical evidence
for cognitive side effects included: topiramate, zonisamide, phenobarbi-
tal, primidone, phenytoin, carbamazepine, divalproex, clonazepam, and
lorazepam. Medications considered lacking robust clinical evidence foradverse cognitive side effects included: levetiracetam, lamotrigine,
oxcarbazepine, pregabalin, gabapentin, and lacosamide [8–10].
Additional medications among patients with epilepsy included
those for managing typical medical conditions among older adults
(e.g., hypertension, acid reﬂux), aswell as a small number of antidepres-
sant and anxiolytic medications. The control group had a similar medi-
cation proﬁle. We would expect the burden of these medications on
cognition to be minimal.
2.2.3. Neuropsychological tests
All study participants completed a comprehensive battery of well-
established neuropsychological tests including:
Global cognition
Mini-Mental State Examination (MMSE) [11]. This is brief
screening measure of cognition that assesses orientation, basic at-
tention, working memory, learning, naming, construction, compre-
hension, and repetition. The maximum score is 30, with scores
below 24 suggesting cognitive impairment.
Mattis Dementia Rating Scale—2 (DRS) [12]. The DRS is a screen-
ing test designed to assess cognition in older adults. It consists of
ﬁve subscales—Attention, Initiation/Perseveration, Construction,
Conceptualization, and Memory. The maximum score is 144, with
lower scores indicating greater cognitive impairment, and scores
less than or equal to 124 suggesting dementia.
Verbal memory
Hopkins Verbal List Learning Test—Revised [13]. Participants are
asked to learn and remember a list of 12 words over the course of
three trials. After a 20-minute delay during which other tasks are
completed, participants are asked to recall as many words from the
list as possible. Total learning and delayed recall are recorded.
Verbal Paired Associates [14]. Participants are asked to learn 14
word pairs over the course of 4 trials. Some pairs are congruent
(e.g., sky–cloud), while others are incongruent (e.g., tree–luck).
They are given the ﬁrst word of the pair and are asked to provide
the other word. After a 30-minute delay, they are again asked to pro-
vide the secondword of the pairing. Total learning and delayed recall
are recorded.
Visual memory
Brief Visuospatial Memory Test—Revised [15]. Participants are
shown a 2 × 3 array of 6 simple geometric designs. They are given
10 s to study the display and are then asked to draw what they can
recall as accurately as possible and in the correct location. Learning
over 3 trials and free recall after a 20-minute delay are recorded.
Attention/psychomotor speed
Trail Making Test—A [16]. Participants are asked to connect a se-
ries of 25 numbered dots in ascending order as quickly as they can
(e.g., 1–2–3, etc.). Time to completion is recorded.
Digit Symbol Coding [17]. Participants are asked to transpose a
coded sequence. They are provided with a key at the top of the
page (e.g., a “1” means “+”) and an array of numbers below, and
are asked to draw the corresponding symbol. Total number of cor-
rect responses in 120 s is recorded.
Executive function
Trail Making Test—B [16]. This test adds a set-shifting component
to Trail Making Test—A and requires participants to alternate be-
tween numbers and letters in ascending order (e.g., 1–A–2–B, etc.).
Time to completion is recorded.
Controlled Oral Word Association [18]. Participants are asked to
generate as many words as they can that begin with a given letter. A
total of three letters are given. Participants have 60 s for each letter
Table 1
Demographic and clinical characteristics.
Characteristic Epilepsy (n = 38) Control (n = 29) p-Value
Age 65.21 (7.87) 61.00 (4.89) .01
Female (%) 52.6% 89.7% b .01
Education 14.79 (2.97) 15.41 (2.13) .34
BDI-II 10.00 (9.78) 3.24 (5.88) b .01
STAI-Trait 55.32 (16.99) 46.52 (12.86) .02
Note. BDI-II = Beck Depression Inventory—II; STAI = State Trait Anxiety Inventory.
Table 2
Seizure and medication characteristics for the group with epilepsy.
Characteristic Mean (SD)/% Range
Age of ﬁrst seizure (years) 40.13 (25.20) 2–85
Seizure duration (years) 25.08 (21.18) b1–60
Seizure frequency (past month) 0.48 (1.26) 0–6
Abnormal MRI 34.2%
Etiology
Idiopathic 47.7%
Trauma 13.2%
Neoplasia 7.9%
Infection 7.9%
Inﬂammatory 2.6%
Neurodevelopmental 2.6%
Vascular/hemorrhagic 7.9%
Unknown 10.5%
Lateralization
Generalized 7.9%
Left 44.7%
Right 23.7%
Bilateral 13.2%
Unknown 10.5%
Localization
Temporal 52.7%
Frontal 10.5%
Multifocal 10.5%
Generalized 7.9%
Unknown 18.4%
AEDs
Monotherapy 47.4%
Polytherapy 52.6%
AEDs with cognitive effects
Zero 52.7%
One 28.9%
Two or more 18.4%
Note. Lateralization and localization were determined based on review of EEG, MRI, and
clinical picture by author AB. AED = antiepileptic drug.
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to a root word already given.
Rey-O Complex Figure—Boston Qualitative Scoring System:
Organization [19]. Participants are asked to copy a ﬁgure that
includes multiple components. An organization score is obtained
through the use of a scoring method that evaluates the approach
taken to complete the drawing.
Language
Boston Naming Test [20]. This test is a measure of confrontation
naming. Participants are shown pictures and asked to name the
depicted item. Item difﬁculty increases from high-frequency objects
to lower-frequency objects. Total correct is recorded.
Animal Fluency [18]. This test is a measure of semantic verbal
ﬂuency. Participants name as many different kinds of animals as
they can in 60 s.
Visuospatial
Rey-O Complex Figure—Boston Qualitative Scoring System: Copy
Presence and Accuracy [19]. The copy of the complex ﬁgure is scored
for the inclusion, accuracy, and placement of all aspects.
Judgment of Line Orientation [21]. This is a task of visuoper-
ception in which participants are asked to match two free standing
lines to a reference point of 11 lines equally spaced in a semicircle
in terms of angle and direction.
2.3. Analyses
With the exception of the MMSE and DRS, raw scores were cor-
rected for age and, when possible, gender and education, using well
established normative data that are consistent with standard clinical
practice in neuropsychology. Speciﬁc tests corrected for age, education,
and gender included: Trail Making Test A & B, Controlled Oral Word
Association, Boston Naming Test, and Animal Fluency [22]. All scores
were then converted into t-scores to facilitate interpretation. Composite
scoreswere created for each cognitive domain by averaging all the scores
within each domain (attention/psychomotor speed, executive function,
language, visual memory, verbal memory, visuospatial skills). Frequency
of cognitive impairmentwas determined by calculating the percentage of
individualswhose domain scoreswere 1.5 standard deviations below the
normative mean scores, as is consistent in clinical practice. Independent-
sample t-test and chi-square analyseswere used to examine groupdiffer-
ences in demographic and clinical characteristics.
For the primary analyses, ANOVAwas used to examine differences in
neuropsychological test performance for all measures except theMMSE
and DRS, for which ANCOVA (controlling for age) was used. Linear re-
gression was then used to identify potential risk factors for cognitive
impairment with the group with epilepsy. For all regression analyses,
the cognitive domain served as the dependent variable and the predic-
tors (i.e., age of onset, seizure frequency in past month, total AEDs, de-
pression, and anxiety) were entered into the model simultaneously.
Secondary analyses were conducted to determine if brain lesions
could explain cognitive impairments. Cognitive performance across do-
mains was compared between a subgroup of the above-described
group with epilepsy without brain lesions (n = 21) and the control
group using ANOVA.
3. Results
3.1. Demographic and clinical characteristics
Table 1 presents the demographic and clinical characteristics of
the groups. When compared with controls, individuals in the group
with epilepsy were signiﬁcantly older and endorsed higher levels of
depression and trait anxiety. The control group had a signiﬁcantly greaterpercentage of females. These differences were not controlled for in fur-
ther analyses as the use of normative data corrected for age and, in
many cases, gender. In addition, depression and anxietywere considered
to be characteristic of epilepsy, and follow-up analyses were planned to
determine the impact of these variables on cognition. There were no dif-
ferences in education between the two groups (p N .05).
Table 2 presents full epilepsy characteristics including location, lat-
eralization, etiology, andmedications.More than half of the participants
were treated with AED polytherapy, and nearly half were on one or
more medications that have been associated with cognitive side effects.3.2. Group differences in neuropsychological test performance
Table 3 presents the neuropsychological test results for the groups.
For the group with epilepsy compared with controls, ANCOVA control-
ling for age revealed poorer MMSE [F(1,64) = 8.16, p = .01] and DRS
[F(1,64) = 6.66, p= .01] total scores. Additionally, the group with epi-
lepsy performed worse than controls on the Attention [F(1,64) = 5.17,
p= .03] andMemory [F(1,64)=4.74, p= .03] subscales of the DRS; no
such pattern emerged for the Initiation/Perseveration, Construction, or
Conceptualization subscales of the DRS.
Table 3
Neuropsychological test performance.
Cognitive domain/test Epilepsy (n = 38) Control (n = 29) p-Value
MMSE (raw) 28.50 (1.75) 29.55 (0.78) .01
Verbal memory 46.76 (11.34) 56.65 (6.43) b .001
Visual memory 40.33 (13.81) 47.71 (11.82) .02
Attention/psychomotor speed 42.42 (10.43) 52.47 (6.24) b .001
Executive function 42.642 (9.06) 50.92 (5.55) b .001
Language 46.78 (10.60) 53.74 (4.90) .002
Visuospatial 48.21 (13.06) 51.43 (8.28) .25
DRS-II total (raw) 136.03 (7.48) 140.72 (3.72) .01
Attention (raw) 35.39 (2.02) 36.41 (1.05) .03
Initiation/perseveration (raw) 35.42 (3.16) 36.72 (1.03) .07
Construction (raw) 5.84 (0.55) 5.97 (0.19) .27
Conceptualization (raw) 36.21 (3.11) 37.62 (1.92) .11
Memory (raw) 23.05 (2.05) 24.17 (1.04) .03
Note. All scores are standardized t-scores based on normative data, unless otherwise
noted. Age was controlled for in analyses using raw scores. MMSE =Mini-Mental Status
Examination, DRS = Dementia Rating Scale.
Table 4
Regression coefﬁcients for predictors of cognitive impairment.
B S.E. β t-Statistic
Visual memory
Age of onset −0.01 0.09 −0.02 −0.11
Seizure frequency −0.89 1.62 −0.08 −0.55
Total medications −2.20 2.81 −0.14 −0.78
Depression 0.16 0.35 0.11 0.44
Anxiety −0.48 0.20 −0.59 −2.34⁎
Language
Age of onset 0.01 0.07 0.02 0.11
Seizure frequency −0.71 1.21 −0.09 −0.59
Total medications −6.01 2.10 −0.49 −2.86⁎
Depression 0.40 0.26 0.37 1.51
Anxiety −0.28 0.15 −0.45 −1.84
Visuospatial
Age of onset −0.10 0.08 −0.20 −1.22
Seizure frequency 1.26 1.48 0.12 0.86
Total medications −9.41 2.56 −0.62 −3.67⁎⁎
Depression 0.24 0.32 0.18 0.76
Anxiety −0.17 0.19 −0.23 −0.94
Note. B= unstandardized coefﬁcient; S.E. = standard error;β=standardized coefﬁcient.
⁎ Indicates p b .05.
⁎⁎ Indicates p b .01.
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also revealed poorer composite domain scores for verbal memory
[F(1,65)=17.68, p b .001], visualmemory [F(1,65)=5.31, p= .02], ex-
ecutive function [F(1, 65)=18.78, p b .001], language [F(1, 65)=10.74,
p b .01], and attention/processing speed [F(1,65) = 21.09, p b .001]; no
such pattern emerged for visuospatial skills [F(1,65) = 1.35, p= .25].
3.3. Prevalence of cognitive impairment
Cognitive impairmentwas found in all domains of cognitive function
for the group with epilepsy, including 39.5% with impairment in visual
memory, 23.7% each in attention and executive function, 18.4% in visuo-
spatial skills, and 15.8% for both verbal memory and language.
3.4. Epilepsy subgroup analyses
To addresswhether cognitive difﬁculties could be explained by brain
lesions, follow-up analyses examined performance of a subset of 21
individuals with epilepsy who did not demonstrate any brain lesions
on MRI. Demographic comparison between the two groups indicated
that similar to the overall ﬁndings, the group with nonlesional epilepsy
was signiﬁcantly older than the control group [t(33.38)= 3.08, p b .01]
and the control group had a greater percentage of females [χ2(n =
50) = 8.80, p b .01]. There were no differences between groups for
years of education (p= .06).
Among the patients with nonlesional epilepsy, clinical impairment
(i.e., 1.5 SD below normative mean) was demonstrated in all domains
including visual memory (42.9%), attention (19%), visuospatial skills
(14.3%), language (19%), executive function (9.5%), and verbal memory
(14.3%). Cognitive performance across domainswas compared between
these cases with nonlesional epilepsy and control participants using
ANOVA. Results indicated that the participants with nonlesional epilep-
sy performedworse on verbalmemory [F(1, 49)=12.69, p b .01], visual
memory [F(1,49)= 4.79, p= .03], executive function [F(1, 49)= 9.22,
p b .01], attention [F(1, 49) = 8.75, p b .01], and language [F(1, 49) =
12.06, p b .01]; no such pattern emerged for visuospatial skills. This
pattern was very similar to that seen for the full sample.
3.5. Predictors of neuropsychological test performance in older adults with
epilepsy
Separate linear regressions were conducted for each cognitive
domain. The full model contained age of seizure onset, estimated num-
ber of seizures in the pastmonth, total number of AEDs, depression, and
anxiety entered into the ﬁrst block as the predictors. The full model
was a signiﬁcant predictor of language [F(5, 32) = 3.42, p = .01],
visuospatial skills [F(5, 32) = 3.63, p = .01], and visual memory[F(5, 32) = 2.93, p= .03] impairment. The full model was not a signif-
icant predictor of any other domain of cognitive function, theMMSE, full
DRS, or any of the DRS subscales.
Examination of individual predictors revealed that the total number
of AEDs predicted language and visuospatial performance, with a great-
er number of AEDs associated with worse performance in those
domains. Follow-up ANOVA was conducted to examine whether there
were differences in cognitive performance between patients on zero,
one, or two or more AEDs with cognitive side effects. Results were non-
signiﬁcant for both language [F(2, 35)= 2.79, p= .08] and visuospatial
[F(2, 35) = 2.60, p= .09] performance. Anxiety signiﬁcantly predicted
visual memory performance (p= .03). See Table 4 for regression coef-
ﬁcients for signiﬁcant omnibus tests.4. Discussion
In this analysis, older adults with epilepsy performed worse on neu-
ropsychological testing across nearly all domains of cognitive function
when compared with older adults without epilepsy. Rates of cognitive
impairment were high among this group, particularly for visual memo-
ry, attention, and executive function. The current ﬁndings expand on
the literature [2–4] by demonstrating a wide range of cognitive deﬁcits
on a comprehensive neuropsychological battery among older adults
with epilepsy compared with controls. This study further elucidates
risk factors for cognitive deﬁcits and examines the contribution of epi-
lepsy characteristics and psychological factors to neuropsychological
test performance in older adults with epilepsy.
We found that the total number of AEDs was associated with worse
language and visuospatial performances. Such ﬁndings are consistent
with previous work showing that AED polytherapy is associated with
worse cognitive outcomes [2,3]. Our follow-up analyses, however,
indicated that a greater number of AEDs with known potential for cog-
nitive side effects were not associated with worse performance on cog-
nitive testing, suggesting contribution from other mechanisms or
factors. These observations lead us to wonder if the total number of
AEDs in use may be a crude marker for the severity of the patient's ep-
ilepsy at the time of testing, or even cumulatively over time. In this re-
gard, it may not be the particular AED in use, but rather the total
number of AEDs that is germane to reﬂecting the burden of epilepsy
on the patient's cognitive performance. This notion remains speculative
based on such modest data as herein.
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lepsy, with the prevalence ranging from 20 to 60% and from 15 to 20%,
respectively [23], though there is limited work examining their contri-
bution to cognitive deﬁcits. In this study, we demonstrated that higher
levels of anxiety were related to poorer visual memory scores. This
ﬁnding is not surprising given the association between anxiety and
cognitive function in other elderly samples [24]. However, to our knowl-
edge, this is the ﬁrst study to demonstrate an independent contribution
of anxiety to cognitive performance in older adults with epilepsy. These
ﬁndings highlight the importance of assessing for anxiety in older adults
with epilepsy, since it may go underdiagnosed in this population, as has
been demonstratedwith depression [25].Moreover, it will be important
for future work to examine the potential impact of treating anxiety on
cognitive outcomes.
A striking ﬁnding of this study is that even among patients with-
out demonstrated brain lesions, cognitive impairment was still quite
prevalent and performance across domains was worse when compared
with the control group. It is possible that epilepsy interacts with the
aging process or with other medical conditions associated with aging
(e.g., hypertension, diabetes) to increase the risk of cognitive decline.
It remains unclearwhich of thepatient's epilepsy characteristics best
predict cognitive outcomes. A recent study [26] found that individuals
with greater seizure frequency performed more poorly on memory
tests. However, these ﬁndings were not corroborated by Piazzini et al.
[3] who found that seizure etiology and frequency were not related to
cognitive function. In the present study, in contrast to our own expecta-
tions, seizure severity and age of onset were not associated with cogni-
tive functioning. One potential reason for these negative ﬁndings, and
perhaps in previous investigations, involves methodological limitations
for adequately characterizing the cumulative burden of the patient's
condition. The course of epilepsy varies greatly between individuals
and over time. It is difﬁcult to capture these differences in one variable,
such as seizure frequency or age of onset, particularly when relying on
the retrospective report of the patient. Future studies should examine
other variables, or combinations of variables, in large samples allowing
for detailed subgroup analyses, to try to better characterize the patient's
burden of epilepsy over time in relation to cognitive outcomes in this
setting.
This study is limited primarily by its relatively small sample size and
cross-sectional design which may hinder its generalizability. Larger
studies that prospectively follow more diverse samples are needed to
further examine possible contributors to cognitive impairment in this
population. This could facilitate exploring the role of lifetime burden
of epilepsy and help elucidate the relative impact of AED use, epilepsy
lateralization, duration/age of onset, and etiologic differences upon cog-
nitive outcomes.
Overall, the current study demonstrated worse cognitive function in
older adults with epilepsy, even in those without brain lesions, com-
paredwithhealthy controls. In addition, AEDpolypharmacy and anxiety
were identiﬁed as predictors of some aspects of cognition. This study
corroborates past ﬁndings, documenting the differences in cognitive
performance among older adults with and without epilepsy, and ex-
tends this work by further characterizing the nature of cognitive deﬁcits
observed among older adults with epilepsy.
In contrast to expectations, AEDs with cognitive side effects did not
heighten the risk for cognitive impairment, which suggests that other
AED-related mechanisms are likely at play, given the predictive power
of the total number of AEDs. The current study identiﬁed anxiety as a
novel risk factor for cognitive deﬁcits among older adults with epilepsy,
and if replicated, suggests that anxiety may be an important treatment
target. Future work to further clarify and understand risk factors forcognitive impairment in this population is warranted to optimize treat-
ment and attenuate risk for cognitive decline.
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